2014
Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based Study
Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based Study. Journal Of Clinical Oncology 2014, 32: 927-934. PMID: 24516021, PMCID: PMC3948095, DOI: 10.1200/jco.2013.51.1261.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerCardiac eventsOlder patientsBreast cancerTrastuzumab completionAdjuvant trastuzumabTreatment completionOlder womenHuman epidermal growth factor receptorAdjuvant trastuzumab useAge 76 yearsDays of therapyMost older patientsSignificant cardiac eventsMultivariable logistic regressionEpidermal growth factor receptorGrowth factor receptorMore comorbiditiesTrastuzumab useComorbidity scorePatient ageHospital admissionOptimal treatmentLower oddsMedicare data
2013
Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC).
Freedman R, Luis I, Lin N, Lii J, Winer E, Keating N. Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 616-616. DOI: 10.1200/jco.2013.31.15_suppl.616.Peer-Reviewed Original ResearchEarly-stage breast cancerBreast cancerAdjuvant trastuzumabCardiac eventsOlder womenTrastuzumab completionOlder patientsHospital admissionDays of therapyTaxane-based therapyMultivariable logistic regressionMore comorbiditiesLower oddsHispanic womenMedicare dataTrastuzumabPatientsTherapyLogistic regressionWomenComorbiditiesChemotherapyAdmissionOne-quarterTreatment